Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
Level 5 - mechanism / opinion, no new human data
Narrative review of PCSK9 biology and alirocumab clinical trials without systematic methodology
PubMed 25244623 · doi:10.1586/14779072.2014.954551
What was done
This paper reviewed the mechanism of PCSK9 inhibition and summarized early clinical trials evaluating alirocumab (SAR236553/REGN727), a monoclonal antibody that prevents PCSK9 from binding LDLR and directing it to lysosomal degradation.
What was found
The abstract reports no numerical data. It notes that alirocumab across various doses and schedules significantly reduced LDL cholesterol as monotherapy and combined with statins or ezetimibe, but clear evidence of cardiovascular outcome reduction remained unproven pending ongoing Phase III trials.
Why it matters
It contextualizes the development of PCSK9 inhibitors as a therapeutic class for patients needing additional LDL cholesterol reduction beyond statins or ezetimibe.
Limits
The paper is a non-systematic review. The abstract provides no sample sizes, effect sizes, statistical comparisons, or safety data, and cardiovascular morbidity/mortality outcomes were unmeasured.
Cited by
- supports PCSK9 inhibitors lower LDL by targeting a protein that breaks down LDL receptors.